Can tadalafil (Cialis) be used to treat pudendal‑nerve‑related pain or dysfunction?

Tadalafil for Pudendal Nerve-Related Issues

Tadalafil is not established as a treatment for pudendal neuralgia or pudendal nerve entrapment, and current evidence does not support its use for this specific indication. The available literature on pudendal nerve disorders does not include tadalafil among recommended therapies, and no clinical trials have evaluated PDE5 inhibitors for pudendal nerve-related pain or dysfunction. 1, 2, 3

Why Tadalafil Is Not Indicated for Pudendal Nerve Disorders

Mechanism Mismatch

• Tadalafil works by enhancing nitric oxide-mediated vasodilation through PDE5 inhibition, which improves blood flow to erectile tissue and relaxes smooth muscle in the bladder neck and prostate. 4, 5
• Pudendal neuralgia is a neuropathic pain syndrome caused by mechanical compression, inflammation, or injury to the pudendal nerve itself—not a vascular or smooth muscle problem that would respond to PDE5 inhibition. 1, 2, 3
• The pathophysiology involves nerve entrapment (most commonly at the Alcock canal), resulting in chronic neuropathic pain that requires nerve-directed therapies, not vasodilators. 3, 6

Established Treatment Paradigm for Pudendal Neuralgia

Current evidence-based management follows a stepwise approach that does not include tadalafil:

First-line (conservative):

• Physical therapy focusing on pelvic floor relaxation
• Neuropathic pain medications (gabapentin, pregabalin, tricyclic antidepressants)
• Activity modification (avoiding prolonged sitting) 2, 3

Second-line (interventional):

• Pudendal nerve blocks (diagnostic and therapeutic, with response rates up to 94%)
• Pulsed radiofrequency ablation (pain reduction in up to 95% of refractory cases) 1, 3

Third-line (surgical):

• Pudendal nerve decompression surgery (neurolysis) for refractory cases
• Neuromodulation/nerve stimulation techniques 1, 3, 6

Important Distinction: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CPPS)

When Tadalafil IS Appropriate

Tadalafil 5 mg daily is FDA-approved and guideline-recommended for chronic prostatitis/chronic pelvic pain syndrome (CPPS), which is a completely different condition from pudendal neuralgia. 4

• CPPS involves prostatic inflammation, pelvic floor muscle dysfunction, and fibrotic changes—not pudendal nerve entrapment. 4, 7, 8
• Tadalafil reduces collagen deposition, increases apoptosis in pelvic tissues, and provides anti-inflammatory effects that address the underlying pathophysiology of CPPS. 4, 8
• Clinical benefit requires a minimum of 4 weeks and is sustained through 12 weeks of therapy in patients with moderate-to-severe CPPS pain (NIH-CPSI pain subscore ≥4). 4, 7

Critical Diagnostic Distinction

• Pudendal neuralgia presents with perineal pain exacerbated by sitting and relieved by standing, follows the pudendal nerve distribution, and responds to pudendal nerve blocks. 1, 2, 3
• CPPS presents with diffuse pelvic/perineal pain, urinary symptoms (urgency, frequency, dysuria), and often coexists with benign prostatic hyperplasia or erectile dysfunction—without the characteristic sitting-aggravated pattern of pudendal neuralgia. 4, 7

Clinical Pitfall to Avoid

Do not prescribe tadalafil for pudendal neuralgia simply because both conditions involve pelvic/perineal pain. The mechanisms, diagnostic criteria, and treatment paradigms are fundamentally different. 1, 2, 3

• If a patient has pudendal neuralgia (diagnosed by Nantes criteria, positive pudendal nerve block, sitting-aggravated pain), refer to a pain specialist or pelvic floor specialist for nerve-directed therapies. 3
• If a patient has CPPS (prostatic inflammation, urinary symptoms, diffuse pelvic pain without nerve entrapment), tadalafil 5 mg daily is an appropriate second-line option after failure of antibiotics or alpha-blockers. 4

Isolated Case Report: Not Sufficient Evidence

• One 2021 case report described a female patient with interstitial cystitis/painful bladder syndrome (IC/PBS)—not pudendal neuralgia—who improved with tadalafil 5 mg daily after failing first- and second-line IC/PBS treatments. 9
• This single case report does not establish efficacy for pudendal nerve disorders and represents a different pelvic pain syndrome (bladder-focused rather than nerve-focused). 9
• No systematic reviews, randomized trials, or guidelines support extrapolating this finding to pudendal neuralgia. 1, 2, 3